Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
103 hedge funds and large institutions have $114M invested in Paratek Pharmaceuticals, Inc. in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 37 increasing their positions, 37 reducing their positions, and 11 closing their positions.
11% more call options, than puts
Call options by funds: $424K | Put options by funds: $382K
0% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 37
2% less capital invested
Capital invested by funds: $116M → $114M (-$2.4M)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
2% less funds holding
Funds holding: 105 → 103 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.46M |
| 2 |
FIG
Fortress Investment Group
New York
|
+$2.41M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.1M |
| 4 |
GAI
General American Investors
New York
|
+$922K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$794K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$3.02M |
| 2 |
Renaissance Technologies
New York
|
-$773K |
| 3 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$712K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$542K |
| 5 |
Morgan Stanley
New York
|
-$418K |
PRTK Hedge Fund Activity: Q4 2021 in Review
103 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2021, worth a combined $114M — down 2.1% from $116M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PRTK and 10 opened new positions — a net loss of 1 holder — while 37 trimmed existing stakes and 37 added.
The largest buyer was AIGH Capital Management, adding an estimated $3.46M. The largest seller was Omega Fund Management, cutting an estimated $3.02M.
- 103 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2021, down from 105 in Q3 2021.
- Funds reported $114M of Paratek Pharmaceuticals, Inc. stock for Q4 2021, down 2.1% quarter-over-quarter.
- 10 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2021 and 11 closed out, a net change of -1 holder.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2021 was AIGH Capital Management, an estimated $3.46M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2021 was Omega Fund Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q4 2021.